Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatment because intermediate-stage HCC encompasses a wide variety of HCCs. Owing to remarkable progress in systemic therapy, including molecular-targeted therapy for advanced-stage HCC, the standard treatment of HCC has recently shifted to systemic therapy. However, it remains controversial as to which treatment should be initially performed for intermediate-stage HCC. In addition, although curative treatment can be considered when the tumor shrinks, the timing of conversion therapy remains uncertain. This review summarizes the advances of HCC treatment and discusses treatment strategies for intermediate-stage HCC.
Keywords: TACE inappropriate; TACE refractory; atezolizumab plus bevacizumab; conversion therapy; durvalumab plus tremelimumab; hepatocellular carcinoma; immune checkpoint inhibitor; intermediate-stage hepatocellular carcinoma; molecular-targeted therapy; transarterial chemoembolization; tyrosine kinase inhibitor; up-to-7 criteria.